The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
|Articles|December 27, 1995
HP taps Danaher as medical products GM
Hewlett-Packard has named Cynthia Danaher as general manager ofits Medical Products group, the Andover, MA, echocardiographyvendor reported last week. Danaher's previous position was generalmanager of HP's imaging systems division. She replaces Gary
Advertisement
Hewlett-Packard has named Cynthia Danaher as general manager ofits Medical Products group, the Andover, MA, echocardiographyvendor reported last week. Danaher's previous position was generalmanager of HP's imaging systems division. She replaces Gary Eichhorn,who replaced Benjamin Holmes in the position earlier this year.
Advertisement
Related to this article
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.
The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.
In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
In a recent interview, Phillip Koo, MD, discussed emerging trends with AI, theranostics and empowered patients, and how these developments may lead to challenges and potential opportunities for radiologists and nuclear medicine physicians.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
2
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
3
Can the Kaiser Score with Breast MRI Improve Clarity for BI-RADS 0 and 4 Assessments on Mammography and Ultrasound?
4
The Reading Room Podcast: Emerging Concepts with AI Integration in Radiology
5